Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase

T.L. Bowles, R. Kim, J. Galante, C.M. Parsons, S. Virudachalam, H-J. Kung and R.J. Bold
International Journal of Cancer (2008), Vol. 123 pages 1950-1955

Arginine deprivation as a targeted therapy for cancer

L. Feun, M. You, C.J. Wu, M.T. Kuo, M. Wangpaichitr, S. Spector and N. Savaraj
Current Pharmaceutical Design (2008), Vol. 14 pages 1049-1057

The relationship of arginine deprivation, argininosuccinate synthetase and cell death in melanoma

N. Savaraj, C. Wu, M.T. Kuo, M. You, M. Wangpaichitr, C. Robles, S. Spector and L. Feun
Drug Target Insights (2007), Vol. 2 pages 119-128

Aberrant regulation of argininosuccinate synthetase by TNF-α in human epithelial ovarian cancer

P.W. Szlosarek, M.J. Grimshaw, G.D. Wilbanks, T. Hagemann, J.L. Wilson, F. Burke, G. Stamp and F.R. Balkwill
International Journal of Cancer (2007), Vol. 121 pages 6-11

Pegylated arginine deiminase: a novel anticancer enzyme agent

L. Feun and N. Savaraj
Expert Opinions on Investigational Drugs (2006), Vol. 15 pages 815-822

In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion

P.W. Szlosarek, A. Klabatsa, A. Pallaska, M. Sheaff, P. Smith, T. Crook, M.J. Grimshaw, J.P. Steele, R.M. Rudd, F.R. Balkwill and D.A. Fennell
Clinical Cancer Research (2006), Vol. 12 pages 7126-7135

Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies

P.A. Ascierto, S. Scala, G. Castello, A. Daponte, E. Simeone, A. Ottaiano, G. Beneduce, V. De Rosa, F. Izzo, M.T. Melucci, C.M. Ensor, A.W. Prestayko, F.W. Holtsberg, J.S. Bomalaski, M.A. Clark, N. Savaraj, L.G. Feun and T.F. Logan
Journal of Clinical Oncology (2005), Vol. 23 pages 7660-7668

Incidence and distribution of argininosuccinate synthetase deficiency in human cancers

B.J. Dillon, V.G. Prieto, S.A. Curley, C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski and M.A. Clark
Cancer (2004), Vol. 100 pages 826-833

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

F. Izzo, P. Marra, G. Beneduce, G. Castello, P. Vallone, V. De Rosa, F. Cremona, C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski, M.A. Clark, C. Ng and S.A. Curley
Journal of Clinical Oncology (2004), Vol. 22 pages 1815-182

Comparative toxicity of arginine deiminase formulated with poly(ethylene glycol) 5000 or 20,000 and the effects of arginine

J.S. Bomalaski, J.L. Ivett, M. Vegarra, F.W. Holtsberg, C.M. Ensor and M.A. Clark
Preclinica (2003), Vol. 1 pages 284-293

Regression of hepatocellular cancer in a patient treated with arginine deiminase

S.A Curley, J.S. Bomalaski, C.M.Ensor, F.W. Holtsberg and M.A. Clark
Hepatogastroenterology (2003), Vol. 50 pages 1214-1216

Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production

B. Dillon, F. Holtsberg, C. Ensor, J. Bomalaski and M. Clark
Medical Science Monitor (2002), Vol. 8 pages BR248-253

Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo

C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski and M.A. Clark
Cancer Research (2002), Vol. 62 pages 5443-5450

Poly(ethylene glycol) (PEG) conjugated arginine deiminase: effects of PEG formulations on its pharmacological properties

F.W. Holtsberg, C.M. Ensor, M.R. Steiner, J.S. Bomalaski and M.A. Clark
Journal of Controlled Release (2002), Vol. 23 pages 259-271

Enzymic degradation of plasma arginine using arginine deiminase inhibits nitric oxide production and protects mice from the lethal effects of tumour necrosis factor α and endotoxin

J.B. Thomas, F.W. Holtsberg, C.M. Ensor, J.S. Bomalaski and M.A. Clark
Biochemical Journal (2002), Vol. 363 pages 581-587